Effect of 5-fluorouracil on excision repair cross-complementing 1 expression and consequent cytotoxicity regulation in human gastric cancer cells

Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth

(2017) Hee Man Kim et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

DNA repair mechanisms in cancer development and therapy

(2015) Alessandro Torgovnick et al.   Frontiers in Genetics

ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines

(2014) WEI LI et al.   Molecular Medicine Reports

Drug Resistance in Cancer: An Overview

(2014) Genevieve Housman et al.   Cancers

A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker

(2013) Masahiro Hirakawa et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)

(2013) Wasaburo Koizumi et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1 and inhibition of platinum–DNA adduct repair

(2012) K Kudo et al.   ONCOGENE

Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2

(2010) Hyunho Yoon et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer

(2010)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203

(2010) Weijing Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

(2009) Narikazu Boku et al.   LANCET ONCOLOGY

Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2

(2009) Jen-Chung Ko et al.   LUNG CANCER

XPF-ERCC1 Participates in the Fanconi Anemia Pathway of Cross-Link Repair

(2009) N. Bhagwat et al.   MOLECULAR AND CELLULAR BIOLOGY

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel

(2008) Lifeng Wang et al.   BMC CANCER

Platinum Resistance: The Role of DNA Repair Pathways

(2008) L. P. Martin et al.   CLINICAL CANCER RESEARCH

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

(2008) Salah-Eddin Al-Batran et al.   JOURNAL OF CLINICAL ONCOLOGY